Compass Therapeutics Inc (CMPX)

$5.16 -0.23 (-4.27%)
Market Cap 917.77M
Revenue (ttm) 850,000.00
Net Income (ttm) -49.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,809.41%
Debt to Equity Ratio 0.00
Volume 1,181,700
Avg Vol 1,908,790
Day's Range N/A - N/A
Shares Out 177.86M
Stochastic %K 11%
Beta 1.44
Analysts Strong Sell
Price Target $12.62

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8099
Address:
80 Guest Street, Suite 601, Boston, United States
Johndoe456
Johndoe456 Dec. 13 at 2:46 PM
$CMPX
0 · Reply
RunnerSignals
RunnerSignals Dec. 13 at 10:47 AM
$CMPX $BRZE $GPCR $OMAB $FOLD show big upside on paper, the real game is timing. Charts are starting to talk before headlines do. Worth a closer look https://stocksrunner.com/target-price-changed
0 · Reply
aitrades23
aitrades23 Dec. 8 at 6:58 AM
$CMPX
1 · Reply
Johndoe456
Johndoe456 Dec. 5 at 1:32 PM
$CMPX
0 · Reply
RunnerSignals
RunnerSignals Dec. 4 at 8:33 PM
$CAPR $MBOT $CMPX $EVTL $TARA biotech boom in motion! Massive upside potential, who is ready to ride the rocket? https://stocksrunner.com/news/2025-12-04-stock-upgrades-today-highlight-top-picks
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 4:10 PM
Cantor Fitzgerald has updated their rating for Compass Therapeutics ( $CMPX ) to Overweight.
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 3:47 PM
Citizens has updated their rating for Compass Therapeutics ( $CMPX ) to Market Outperform with a price target of 10.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 3 at 3:44 PM
$CMPX Share Price: $5.33 Contract Selected: Mar 20, 2026 $6.0 Calls Buy Zone: $1.02 – $1.26 Target Zone: $1.71 – $2.10 Potential Upside: 59% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 12:35 PM
Canaccord Genuity has adjusted their stance on Compass Therapeutics ( $CMPX ), setting the rating to Buy with a target price of 10.
0 · Reply
notreload_ai
notreload_ai Dec. 3 at 12:04 PM
Multiple analysts initiate bullish coverage on $CMPX , highlighting promising data for lead drug tovecimig and strong pipeline potential. https://notreload.xyz/compass-therapeutics-rated-outperform-after-trial-success/
0 · Reply
Latest News on CMPX
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 4, 2025, 5:08 PM EST - 9 days ago

Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 4, 2025, 4:48 PM EST - 9 days ago

Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Compass Therapeutics to Participate in Upcoming December Investor Events

Nov 25, 2025, 8:00 AM EST - 19 days ago

Compass Therapeutics to Participate in Upcoming December Investor Events

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:30 AM EST - 5 weeks ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 4, 2025, 9:00 AM EST - 5 weeks ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics to Participate in Upcoming November Investor Events

Nov 3, 2025, 8:00 AM EST - 5 weeks ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:06 AM EDT - 3 months ago

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Aug 13, 2025, 9:40 AM EDT - 4 months ago

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 10:28 PM EDT - 4 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Compass Therapeutics Announces Proposed Public Offering

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 4 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Aug 8, 2025, 4:01 PM EDT - 4 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

May 12, 2025, 9:51 PM EDT - 7 months ago

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in Upcoming May Investor Events

May 6, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 8 months ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 9 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 9 months ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 10 months ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 9, 2024, 12:54 PM EST - 1 year ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Compass Therapeutics: Pointing Right At Some Tough Cancers

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 23, 2024, 5:05 PM EDT - 1 year ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 9, 2024, 12:00 PM EDT - 1 year ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Compass Therapeutics Provides Corporate Update

Jan 5, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics Provides Corporate Update

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:30 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 22, 2023, 4:05 PM EDT - 2 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

May 4, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Johndoe456
Johndoe456 Dec. 13 at 2:46 PM
$CMPX
0 · Reply
RunnerSignals
RunnerSignals Dec. 13 at 10:47 AM
$CMPX $BRZE $GPCR $OMAB $FOLD show big upside on paper, the real game is timing. Charts are starting to talk before headlines do. Worth a closer look https://stocksrunner.com/target-price-changed
0 · Reply
aitrades23
aitrades23 Dec. 8 at 6:58 AM
$CMPX
1 · Reply
Johndoe456
Johndoe456 Dec. 5 at 1:32 PM
$CMPX
0 · Reply
RunnerSignals
RunnerSignals Dec. 4 at 8:33 PM
$CAPR $MBOT $CMPX $EVTL $TARA biotech boom in motion! Massive upside potential, who is ready to ride the rocket? https://stocksrunner.com/news/2025-12-04-stock-upgrades-today-highlight-top-picks
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 4:10 PM
Cantor Fitzgerald has updated their rating for Compass Therapeutics ( $CMPX ) to Overweight.
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 3:47 PM
Citizens has updated their rating for Compass Therapeutics ( $CMPX ) to Market Outperform with a price target of 10.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 3 at 3:44 PM
$CMPX Share Price: $5.33 Contract Selected: Mar 20, 2026 $6.0 Calls Buy Zone: $1.02 – $1.26 Target Zone: $1.71 – $2.10 Potential Upside: 59% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 12:35 PM
Canaccord Genuity has adjusted their stance on Compass Therapeutics ( $CMPX ), setting the rating to Buy with a target price of 10.
0 · Reply
notreload_ai
notreload_ai Dec. 3 at 12:04 PM
Multiple analysts initiate bullish coverage on $CMPX , highlighting promising data for lead drug tovecimig and strong pipeline potential. https://notreload.xyz/compass-therapeutics-rated-outperform-after-trial-success/
0 · Reply
RunnerSignals
RunnerSignals Dec. 1 at 9:34 PM
$ABBV $BKU $BROS $CCL $CMPX upgrades fueling market buzz! Traders are watching closely! https://stocksrunner.com/news/2025-12-01-stock-upgrades-today-highlight-top-momentum-plays
0 · Reply
Magic8BallResponse
Magic8BallResponse Dec. 1 at 3:19 PM
$CMPX Joined the party....
0 · Reply
WonderfulMongoose
WonderfulMongoose Nov. 30 at 3:31 AM
$CMPX weekly Lol
0 · Reply
Lexcol
Lexcol Nov. 24 at 3:36 PM
$OCGN Time to buy See also $CMPX
0 · Reply
Lexcol
Lexcol Nov. 24 at 3:10 PM
$CMPX 5.20 today
0 · Reply
Lexcol
Lexcol Nov. 19 at 3:44 PM
$CMPX
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 16 at 11:09 PM
$CMPX $CNBS $COF $COHR $COIN
1 · Reply
Marvinvaca
Marvinvaca Nov. 15 at 12:00 PM
$CMPX https://youtu.be/P7TnHzJ6_20?si=Wq209zn6G416N8SW
0 · Reply
Lexcol
Lexcol Nov. 12 at 3:13 PM
$CMPX $OCGN
0 · Reply
Lexcol
Lexcol Nov. 12 at 1:59 PM
$CMPX 5$ today
0 · Reply
Lexcol
Lexcol Nov. 11 at 8:59 PM
$OCGN $CMPX
0 · Reply